12:00 AM
 | 
Aug 27, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xience Xpedition regulatory update

Abbott received CE Mark approval for and immediately launched Xience Xpedition everolimus eluting coronary stent system to treat coronary artery...

Read the full 80 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >